Austrian SME building brain-computer interface systems for clinical rehabilitation, consciousness diagnostics, and emerging XR-neuroscience applications.
g.tec is an Austrian SME that develops brain-computer interface (BCI) hardware and software for medical and research applications. Their core business is building EEG-based neurotechnology systems used in clinical rehabilitation (particularly stroke recovery), diagnosis of disorders of consciousness, and epilepsy monitoring. They bridge the gap between neuroscience research and commercial medical devices, providing the signal acquisition and processing technology that enables brain-controlled rehabilitation systems like exoskeletons and paired associative stimulation setups. More recently, they have expanded into extended reality (XR) applications combining their neural signal expertise with immersive environments.
RecoveriX (their largest coordinated project at EUR 1.86M) focused on motor recovery via paired associative stimulation; PRO GAIT addressed stroke gait rehabilitation with EEG and exoskeletons; ComAlive targeted BCI-based communication for consciousness disorders.
DoCMA focused on evidence-based diagnosis and care management for DoC patients; ComAlive (coordinated by g.tec) combined diagnosis, prediction, and rehabilitation for DoC.
Their EEG hardware and software platform underpins RecoveriX, DoCMA, PRO GAIT, HOPE (epilepsy EEG/MEG), and RHUMBO (biometric brain signals for decision-making research).
Participated in GrapheneCore3 and the 2D Experimental Pilot Line (2D-EPL), both under the Graphene Flagship, likely contributing neural electrode or sensor expertise.
GuestXR (2022-2025) combines XR with neuroscience and social psychology; RHUMBO explored mixed reality technologies with biometric brain signals.
BeMAGIC training network explored wireless cell stimulation via magnetoelectric nanomaterials, relevant to future implantable neural interfaces.
In their earlier H2020 projects (2016–2019), g.tec focused squarely on clinical neurorehabilitation and diagnostics — stroke recovery, disorders of consciousness, epilepsy detection, and neuro-business applications using EEG and exoskeletons. From 2020 onward, their participation shifted toward advanced materials (graphene electrodes, magnetoelectric nanomaterials) and immersive technologies (extended reality, augmented reality). This evolution suggests they are moving from purely clinical BCI applications toward next-generation neural interfaces built on new materials and embedded in XR environments.
g.tec is positioning itself at the intersection of neural interfaces and immersive XR, while investing in next-generation electrode materials through graphene and magnetoelectric projects — expect future work combining all three.
g.tec primarily joins consortia as a specialist partner (8 of 10 projects), providing their BCI hardware/software platform to larger research teams. They have coordinated two projects (RecoveriX and ComAlive), both in their core domain of consciousness disorders and motor rehabilitation. With 246 unique partners across 24 countries, they maintain a broad European network rather than relying on a small circle — this makes them an accessible and experienced consortium partner for neurotechnology-related proposals.
g.tec has collaborated with 246 different organizations across 24 countries, indicating a wide and diverse European network. Their participation in large flagships (Graphene) and multi-partner MSCA networks gives them connections spanning clinical, academic, and industrial partners across the continent.
g.tec is one of very few European SMEs that both manufactures BCI hardware and actively participates in clinical research consortia — most competitors are either pure device vendors or pure research labs. Their 10-project H2020 track record demonstrates they can deliver technology components reliably within large consortia, and their recent move into graphene-based neural sensors and XR puts them at a rare intersection that few organizations occupy. For consortium builders, they offer a commercially grounded partner who understands both the engineering and clinical sides of neurotechnology.
